Associate Professor Libby Roughead

Quality Use of Medicines Mapping Project

Quality Use of Medicines and Pharmacy Research Centre

Quality Use of Medicines - A Decade of Research, Development & Service Activity 1991-2001 PHARM, written by Libby Roughead

The Second National Report on Patient Safety: Improving Medication safety Safety and Quality Council, primarily written by Libby Roughead, Susan Semple

Measurement of the quality use of medicines component of the national medicines policy

The value of pharmacist professional services in the community setting. A systematic review of the literature 1990 – 2002.

PhD

M.App.Sc. (Health Sciences)

B. Pharm

Grad Dip Health Promotion

• Public policy concerning medicines
• Quality Use of Medicines / Rational Drug Use
• Pharmaceutical Promotion
• Pharmacoepidemiology

Morgan S, Kennedy J, Boothe K, McMahon M, Watson D, Roughead E. Toward an understanding of high performance pharmaceutical policy systems: a ‘triple-A’ framework and example analysis. The Open Health Services and Policy Journal (in press, accepted Feb 2, 2009)

Roughead EE, Ramsay EN, Priess K, Barratt JD, Ryan P, Gilbert AL. Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates Pharmacoepi Drug Saf 2009; 18: 69-75

Roughead EE, Ramsay EN, Pratt NL, Ryan P, Gilbert AL. Proton pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust. 2009; 190: 114-116.

Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepi Drug Saf. 2008; 17 (11): 1091-1099.

Vitry A, Wong SA, Roughead EE, Ramsay E, Barratt J. Validity of medication-based comorbidity indices in the Australian elderly population. Aust N Z J Pub Health (in press, accepted Jan 2009)

Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia BMC Public Health 2008, 8:221

Roughead EE, Ramsay E, Pratt N, Gilbert AL. Non-steroidal anti-inflammatory drug use in those at risk of renal adverse events: trends in Australian veterans. Drug Safety 2008;31:997-1003.

Morden NE, Zerzan JT, Rue T, Heagerty PJ, Roughead E, Soumerai S, Ross-Degnan D, Sullivan SD. Medicaid Prior Authorization and Controlled-Release Oxycodone. Med Care 2008; 46: 573-580.

Roughead EE, Vitry AI, Gilbert AL. The Australian funding debate on quadrivalent HPV vaccine: A case study for the national pharmaceutical policy. Health Policy. 2008 May 9.

Kalisch L, Roughead EE, Gilbert AL. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia" Pharmacoepi Drug Saf 2008; 17: 620-625.

Roughead EE, Woodward M, Gilbert AL. Medicine use by Australian veterans resident in aged-care facilities. J Pharm Pract Res 2008; 38: 14-18

Hughes CM, Roughead E, Kerse N. Beyond regulation: international strategies to improve use of medicines for older people in long-term care. Healthcare Policy 2008; 3: 1-14.

Roughead EE, Barratt J, Gilbert AL, Peck R, Killer G. Diabetes processes of care in the Australian veteran population. Diabetes Res Clin Pract. 2008; 79: 299-304.

Roughead EE, Pratt N, Peck R, Gilbert AL. Improving medication safety: Influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners. Pharmacoepidemiol Drug Saf 2007 May 3;16(7):797-803

Roughead EE, Lopert R, Sansom LN. Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and USA. Value in health 2007; 10(6):514-20.

Roughead E.E., Anderson B. Gilbert, A.L. Potentially inappropriate prescribing amongst Australian veterans and war widows/widowers. Intern Med J 2007; 37: 402-405

Roughead EE, Pratt N, Gilbert AL. Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes. Br J Clin Pharmacol 2007 Jul;64(1):100-4.

Roughead EE, McDermott B, Gilbert AL. Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Aust N Z J Psychiatry 2007; 41:366-370

Zerzan JT, Morden NE, Soumerai S, Ross-Degnan D, Roughead E, Zhang F, Simoni-Wastila L, Sullivan SD. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care. 2006 Nov;44(11):1005-10

Roughead EE. Enhancing early uptake of drug evidence into primary care. Expert Review of Pharmacoeconomics & Outcomes Research 2006 6 (6) 661-671.

Roughead EE, Zhang F, Ross-Degnan D, Soumerai S. Differential effect of early or late implementation of prior authorization policies on use of Cox II inhibitors. Med Care 2006 44(4):378-382.

Morgan S, McMahon M, Mitton C, Roughead EE, Kirk R, Kanavos P, Menon D. Centralized Drug Review Processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff 2006; 25: 337-347.

Harvey K.J., Vitry, A.I., Roughead E., Aroni A., Ballenden N., Faggotter R. Pharmaceutical advertisements in prescribing software: an analysis. MJA 2005; 183: 75-79.

I am able to provide media comment in the following areas of expertise:

Discipline: Pharmacy

• Adverse drug events
• Pharmaceutical Promotion
• Quality Use of Medicines